Drug intelligence / Profile preview

ARC-706

Development stage: Unknown
Lead developer: Archeus Technologies
Modality: Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics

Overview

ARC-706 is a radiopharmaceutical agent developed by Archeus Technologies for use in combination with certain validated immunotherapies across various cancer types. Preclinical data suggest it may produce curative responses and generate immune memory against cancers resistant to immunotherapy. It is part of a theranostic pair with the companion diagnostic ARC-166.

Beyond the preview

Go deeper on ARC-706.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARC-706.

Explore the full profile